Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals develops pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News about ARMP centers on its late clinical-stage phage pipeline, including AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for Pseudomonas aeruginosa, FDA designations and regulatory interactions, scientific publications on phage structure, and clinical program updates.
Company updates also cover financial results, research and development spending, grant-supported program activity, credit agreement and warrant amendments with Innoviva-related entities, and board or annual-meeting governance matters. Armata describes in-house phage-specific cGMP manufacturing as part of its development model.
Armata Pharmaceuticals (NYSE American: ARMP) reported multiple milestones supporting the planned Phase 3 superiority study of AP-SA02, its intravenous multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The company submitted the complete Phase 3 protocol and comprehensive responses to all U.S. FDA comments from the End-of-Phase 2 meeting, covering clinical, Chemistry, Manufacturing and Controls, and regulatory topics. Armata also completed four engineering runs of AP-SA02 at its in-house cGMP facility in Los Angeles, with production of Phase 3 clinical trial material as the next step. In June 2026, Armata received an additional $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under this award to $28.7 million to support Phase 3 preparations. The pivotal trial remains on track to initiate in the second half of 2026 and is intended to support a future BLA. The company promoted David House to Chief Financial Officer to support late-stage development and strategy execution.
Armata Pharmaceuticals (NYSE American: ARMP) reported that the U.S. FDA has agreed to an Initial Pediatric Study Plan (Agreed iPSP) for AP-SA02 as adjunct treatment of complicated Staphylococcus aureus bacteremia (SAB) in pediatric patients, fulfilling a key regulatory requirement before a future Biologics License Application (BLA).
The Agreed iPSP defines a pediatric program for patients up to 17 years, aligned with the adult SAB indication. According to Armata, FDA, under the Pediatric Research Equity Act and aligned with EMA frameworks, agreed that pediatric studies will be deferred until adult safety and efficacy data are generated in a planned Phase 3 program, expected to initiate in the second half of 2026.
Following completion of the adult Phase 3 study, Armata plans a single multicenter, open-label pediatric trial to evaluate safety, tolerability and clinical response, creating a structured pathway to potentially expand AP-SA02 use into pediatric populations while prioritizing patient safety.
Armata Pharmaceuticals (NYSE American: ARMP) received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense for lead candidate AP-SA02, raising the award total to $28.7 million.
The funds support Phase 3 readiness of intravenous AP-SA02 for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA, with plans to initiate a Phase 3 superiority study in the second half of 2026.
Armata Pharmaceuticals (NYSE American: ARMP) reported first quarter 2026 results and a corporate update. Grant revenue rose to $0.8 million, R&D expenses to $6.1 million, G&A to $3.5 million, and loss from operations to $8.8 million. Net loss was $115.3 million versus $6.5 million a year earlier.
The company is preparing a Phase 3 AP-SA02 study in complicated S. aureus bacteremia, targeting initiation in the second half of 2026. AP-SA02 received FDA Fast Track and QIDP designations. Armata entered a new $25 million secured credit agreement with Innoviva maturing in 2029 and extended prior Innoviva credit maturities to 2027. Cash and equivalents were $4.8 million at March 31, 2026.
Armata Pharmaceuticals (NYSE: ARMP) announced the FDA has granted Fast Track Designation to AP-SA02, its IV multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (MSSA and MRSA). Fast Track allows more frequent FDA engagement, rolling BLA review, and potential eligibility for Accelerated Approval and Priority Review.
The company plans to initiate a Phase 3 superiority study anticipated in the second half of 2026 and expects increased FDA interactions during clinical development.
Armata Pharmaceuticals (ARMP) announced a peer-reviewed publication in Communications Biology titled "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection." The paper describes near-atomic cryo-EM structures of phage P7-1, a component of Armata's AP-PA02 phage cocktail.
The study reports dual tail-fiber architecture that locks the tail sheath to preserve stability and a conformational cascade that releases the lock on host recognition. Armata notes AP-PA02 is being developed for chronic Pseudomonas aeruginosa respiratory infections and has completed two Phase 2 trials, SWARM-P.a. and Tailwind.
Armata Pharmaceuticals (NYSE American: ARMP) appointed Daniel B. Gilmer, Ph.D. to its Board of Directors, effective April 24, 2026. Dr. Gilmer currently serves at Pfizer and has experience leading commercial launches, quality oversight for 50+ U.S. brands, and advancing anti-infective programs including work on PAXLOVID and phage-related research.
The appointment adds commercial and access expertise intended to support Armata's late clinical-stage, bacteriophage therapeutic pipeline against antibiotic-resistant infections.
Armata Pharmaceuticals (NYSE American: ARMP) reported fourth-quarter and full-year 2025 results for the period ended December 31, 2025. Key fourth-quarter figures include a net loss of $124.3 million (loss per share $(3.42)), cash and equivalents of $14.1 million, grant revenue of $1.1 million, and R&D expense of approximately $6.1 million.
The quarter included a $105.8 million non-cash fair-value loss on a convertible loan and a $5.4 million impairment on leased facilities. Debt maturities were extended to June 1, 2027 and Innoviva warrants were amended to expire January 26, 2031. Auditor included a going-concern explanatory paragraph.
Armata Pharmaceuticals (NYSE American: ARMP) delayed its Q4 and full‑year 2025 financial results and expects to file its Form 10‑K on or before March 31, 2026. The company received QIDP designation for AP‑SA02 and completed an End‑of‑Phase 2 response enabling a planned Phase 3 superiority trial anticipated to start in H2 2026. Armata commissioned a 56,000 sq ft cGMP facility in Los Angeles with full production runs completed. Phase 2a diSArm data presented at IDWeek 2025 showed higher early cure rates and favorable tolerability for AP‑SA02 versus BAT.
Armata Pharmaceuticals (NYSE: ARMP) announced that the FDA granted QIDP designation to AP-SA02 for intravenous adjunct treatment of complicated bacteremia caused by MSSA or MRSA on February 23, 2026. The designation makes AP-SA02 eligible for five additional years of Hatch-Waxman market exclusivity and potential Fast Track, priority and rolling review. Armata plans to request Fast Track and to initiate a Phase 3 superiority study in H2 2026.